CAJ | 학술논문

目的运用ROC曲线评价CA153及CEA在诊断三阴乳腺癌中的应用价值.方法运用电化学发光免疫分析法对104例三阴乳腺癌患者(三阴组)、510例非三阴乳腺癌患者(非三阴组)以及50例乳腺良性疾病患者的血清标本进行检测,比较3组结果间的差异,并应用ROC曲线评估CA153及CEA在三阴乳腺癌中的诊断价值.结果三阴乳腺癌组患者的血清CA153水平显著高于非三阴乳腺癌及乳腺良性肿瘤组(P＜0.05);CEA水平显著高于乳腺良性肿瘤组(P＜0.05),与非三阴乳腺癌组相比,差异无统计学意义(P＞0.05);对实验数据进行ROC曲线分析显示,CA153单独诊断三阴乳腺癌的ROC曲线下面积(AUC)为0.735,CEA单独诊断三阴乳腺癌的ROC曲线下面积为0.569,两者联合诊断的ROC曲线下面积为0.795.结论 CA153在诊断三阴乳腺癌中具有一定价值,可作为三阴乳腺癌诊断指标之一;与CEA联合检测意义不大,应寻求另一种或多种相关的肿瘤标记物联合检测.
목적 운용ROC곡선평개CA153급CEA재진단삼음유선암중적응용개치.방법 운용전화학발광면역분석법대104례삼음유선암환자(삼음조)、510례비삼음유선암환자(비삼음조)이급50례유선량성질병환자적혈청표본진행검측,비교3조결과간적차이,병응용ROC곡선평고CA153급CEA재삼음유선암중적진단개치.결과 삼음유선암조환자적혈청CA153수평현저고우비삼음유선암급유선량성종류조(P＜0.05);CEA수평현저고우유선량성종류조(P＜0.05),여비삼음유선암조상비,차이무통계학의의(P＞0.05);대실험수거진행ROC곡선분석현시,CA153단독진단삼음유선암적ROC곡선하면적(AUC)위0.735,CEA단독진단삼음유선암적ROC곡선하면적위0.569,량자연합진단적ROC곡선하면적위0.795.결론 CA153재진단삼음유선암중구유일정개치,가작위삼음유선암진단지표지일;여CEA연합검측의의불대,응심구령일충혹다충상관적종류표기물연합검측.
Objective To evaluate the diagnostic value of CA153 and CEA in triple negative breast cancer (TNBC) by ROC analysis.Methods 104 women with triple negative breast cancer were entered into the study as a triple negative group,510 with non-triple negative breast cancer a non-triple negative group,and 50 with breast benign tumor a control group.CA153 and CEA was detected by chemiluminescence immumoassay and their results of the three groups were compared.The diagnostic critical value of triple negative breast cancer (TNBC) was evaluated by ROC analysis.Results The serum level of CA153 was significantly higher in the triple negative group than in the non-triple negative group and the control group (P＜0.05).The serum level of CEA was significantly higher in the triple negative group than in the control group(P＜0.05) but not than in the non-triple negative group (P＞0.05).ROC curve analysis showed that the area under curve of only CA153 was 0.735,CEA 0.569,and both CA153 and CEA 0.795.Conclusions CA153 can be a diagnostic index of triple negative breast cancer (TNBC).Combined detection of CA153 and CEA cannot increase the detection rate.We should find more useful tumor markers to improve the diagnosis and differential diagnosis of triple negative breast cancer (TNBC).